Documented regulatory authorship and statistical synergy across high-complexity clinical indications—from oncology and neurodegenerative disorders to acute respiratory care and pediatric endocrinology.
Over 23 years of hands-on experience authoring protocols, CSRs, safety narratives, and submission dossiers for global trial programs.
Deep experience navigating complex solid tumor and hematologic malignancy protocols, handling multi-arm adaptive trials, immune-related response criteria (irRECIST), and intricate time-to-event statistical endpoints (Overall Survival [OS], Progression-Free Survival [PFS], Duration of Response [DOR]).
Mastery over intricate subjective rating scales, cognitive batteries, electronic clinical outcome assessments (eCOA), and long-term functional safety profiles in complex central nervous system trials.
Extensive track record during the pandemic and beyond authoring clinical trial protocols, CSRs, and publications investigating novel therapeutics and vaccines in acute and chronic pulmonary disease.
Navigating the heightened ethical and methodological requirements of pediatric trials, rare disease natural histories, and chronic endocrinology management.
Expert documentation under the stringent standards of the EU Medical Device Regulation (EU MDR 2017/745), FDA Investigational Device Exemptions (IDE), and Premarket Approvals (PMA).
From First-in-Human dose escalation protocols to registrational Phase III global dossiers and real-world post-marketing observational registries.
